TheraRadar
Data updated: May 26, 2026

LIQREV (sildenafil citrate)

Trial Activity: Declining 4 active trials
Urology Approved 2023-04-28
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. conducting 12 trials (32%)
43 indications explored (Broad Platform)
→ pulmonary arterial hypertension (7 trials)
→ pulmonary arterial hypertention (3 trials)
→ post-concussion syndrome (2 trials)
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Discontinued
First Approved
2023-04-28
Patent Cliff
2038

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SUSPENSION

Companies

CMP DEV LLC
Active Ingredient: SILDENAFIL CITRATE

LIQREV Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2023 to 2023
Apr 2023 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer
FDA Letter Label

What LIQREV Treats

1 FDA approvals

Originally approved for its first indication in 2023 .

  • Other (1)
📋

Clinical Trial Registry

29 trials
Trial Sponsor ID Phase Status Title
NCT05061368 Pro00108944 Ph 2 recruiting Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD
NCT04565925 20-0197 Ph 2 recruiting Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
NCT06178523 RES/2024/1 Ph 4 completed Cost-effective Treatment of Unexplained Infertility
NCT04898114 Neb-Mag-2 Ph 1, Ph 2 recruiting Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn
NCT01817751 results posted MCC-14816 HM14816, NCI-2013-00705 Ph 2 completed Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
NCT04169191 SANE-02 SANE-02 Ph 1 active not recruiting Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia
NCT00871065 0165-08-FB Ph 2 withdrawn Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm
NCT05846906 REC-H-PhBSU-21015 Ph 2, Ph 3 completed Effect of Oral Sildenafil Citrate on Improvement of Endometrial Thickness
NCT03686813 results posted Pro00100971 Ph 2 completed Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
NCT03417492 827103 Ph 1 terminated Cerebrovascular Reactivity in American Football Players
NCT02060487 AFFILIATE results posted A1481324 2013-004362-34, AFFILIATE Ph 4 terminated Effects of Oral Sildenafil on Mortality in Adults With PAH
NCT01247805 A1481293 EudraCT 2010-023521-38 Ph 1 completed A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
NCT01656798 A1481313 Ph 1 completed Food Effect Study For New Formulation
NCT00430716 results posted A1481244 2006-006748-76 Ph 4 terminated To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
NCT03598140 results posted STU 032018-063 Ph 2 terminated Sildenafil Treatment for Mild TBI
NCT02466802 MCC-13-09812 HM20004297, NCI-2015-01101 Ph 1 completed Study of Regorafenib and Sildenafil for Advanced Solid Tumors
NCT03766594 SURPL Ph 1 completed Sildenafil Citrate in Early Unexplained Recurrent Pregnancy Loss
NCT01950923 IRB00021729-1 NCI-2013-00988, P30CA012197 Ph 1 completed Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer
NCT02620995 CAAE 17663813.4.0000.5272 Ph 4 completed Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction
NCT03431649 TAshirley Ph 4 completed Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children
NCT02590536 SFGR Ph 3 completed A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
NCT02129725 results posted 110206-substudy Ph 4 completed Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.
NCT02628847 53515 Ph 1 terminated Sildenafil and Stroke Recovery
NCT01347008 results posted FAPESP 2011/00012-3 Ph 3 completed Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
NCT00862043 SIOVAC FIBHGM-SIOVAC 2007-007033-40, EC07-90772 Ph 4 completed Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease
NCT02845388 Ainshams2015Omar Ph 2 completed Sildenafil Citrate in Frozen Embryo Transfer
NCT01830790 results posted Pro00042897 Ph 2 terminated Effects of Sildenafil on Choroidal Thickness in AMD
NCT01219023 JADE Pro00021480 Ph 1 completed Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
NCT01122264 results posted 13085 H6D-EW-LVIJ Ph 4 completed A Study in Patients With Erectile Dysfunction
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LIQREV FDA Label Details

View full patent landscape →
5 OB patents · 1 families · 28 international docs across 9 countries

LIQREV Patents & Exclusivity

Latest Patent: Dec 2038

Patents (5 active)

US11337979 Expires Dec 24, 2038
US11464778 Expires Dec 24, 2038
US12186321 Expires Dec 24, 2038
US11759468 Expires Dec 24, 2038
US12005062 Expires Dec 24, 2038
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for LIQREV

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2038
  • • 5 active patents

Trial Analysis

  • • 37 total trials
  • • Stage: Declining

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA214952 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment